WebAug 25, 2024 · August 25, 2024 - 7:00 am. SEATTLE and TORONTO, Aug. 25, 2024-- CTI BioPharma Corp. (Nasdaq: CTIC) (CTI) and DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a … WebSep 30, 2024 · (2024-11-07 NDAQ:CTIC) CTI BioPharma Reports Third Quarter 2024 Financial Results ... CTI will host a conference call and webcast to review its third quarter 2024 financial results and provide an update on business activities today ... Statements included in this press release that are not historical in nature are forward-looking …
2024-02-23 NDAQ:CTIC Press Release CTI BioPharma Corp.
WebFDA news releases, media contacts, speeches, meetings and workshops, and other ways that FDA engages with the public. WebFeb 23, 2024 · SEATTLE, Feb. 23, 2024 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its fourth quarter and full year 2024 financial results will be reported on Monday, … list of car accessories
2024-02-28 NDAQ:CTIC Press Release CTI BioPharma Corp.
WebMar 6, 2024 · Fourth Quarter and Full Year 2024 Financial Results. Net Product Sales: Net product sales of $21.1 million and $53.9 million for the three months and year ended December 31, 2024, respectively ... WebMar 6, 2024 · RECENT CTI PRESS RELEASES. View All. RECENT CTI PRESS RELEASES. 04/12/2024 CTI BioPharma to Participate in Two Upcoming Investor … Myelofibrosis is a rare, heterogeneous, debilitating, progressive bone marrow … Press Releases; Events & Presentations; Financial Information ; Corporate … Attention Recruiters: Employment is managed through its Human Resources … Pacritinib for Other Indications. Graft Versus Host Disease. The combination of … CTI BioPharma focuses on the acquisition, development and commercialization of … Adam R. Craig, M.D., Ph.D., M.B.A. is President. Chief Executive Officer and … The PRE-VENT study was a randomized, double-blind, placebo-controlled … At CTI, we are resolute in our commitment to deliver new medicines to patients with … CTI BioPharma focuses on the acquisition, development and commercialization of … Web1 day ago · CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced ... images of the easter story